Literature DB >> 27351559

[New treatment options for chronic pruritus].

C Zeidler1, B Pfleiderer2, S Ständer3.   

Abstract

Prevalent in 14-17 % of the population, chronic pruritus is among the most common and stressful symptoms in medicine. In spite of new findings regarding the origin and chronification of the symptom, therapy remains a great challenge. There is a lack of approved therapies that provide rapid and efficient reduction of pruritus. As a result, the affected patients suffer a long time (even months to years), and somatic (scratch lesions, super infections, sleep disorders) and psychosomatic disorders develop. Interdisciplinary cooperation with various specialists is important not just for these reasons, but also due to different etiologies of the symptom and common comorbidities. In addition, there remains a great need for uniformly devised, clinically controlled studies, recommendations and guidelines. New therapeutic approaches are currently being verified in clinical trials. This allows for future prospects of possible new and partially targeted therapies. This article provides a summary of current therapeutic options based on case series, individual randomized controlled trials and the current S2K guideline.

Entities:  

Keywords:  Anticonvulsants; Comorbidities; Naltrexone; Neurokinin-1 receptor antagonist; Prurigo

Mesh:

Substances:

Year:  2016        PMID: 27351559     DOI: 10.1007/s00105-016-3828-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  61 in total

1.  Treatment of prurigo nodularis with topical capsaicin.

Authors:  S Ständer; T Luger; D Metze
Journal:  J Am Acad Dermatol       Date:  2001-03       Impact factor: 11.527

Review 2.  Transient receptor potential ion channels as participants in thermosensation and thermoregulation.

Authors:  Michael J Caterina
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-09-14       Impact factor: 3.619

3.  Successful treatment of refractory aquagenic pruritus with naltrexone.

Authors:  Sarah Ingber; Paul D Cohen
Journal:  J Cutan Med Surg       Date:  2005-10       Impact factor: 2.092

4.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

5.  Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.

Authors:  Atieh Makhlough; Shahram Ala; Zohreh Haj-Heydari; Zahra Kashi; Alireza Bari
Journal:  Iran J Kidney Dis       Date:  2010-04       Impact factor: 0.892

6.  Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden.

Authors:  S Ständer; A Stumpf; N Osada; S Wilp; E Chatzigeorgakidis; B Pfleiderer
Journal:  Br J Dermatol       Date:  2013-06       Impact factor: 9.302

Review 7.  Drug evaluation review: dupilumab in atopic dermatitis.

Authors:  Jennifer D Hamilton; Benjamin Ungar; Emma Guttman-Yassky
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

8.  Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.

Authors:  Sonja Ständer; Barbara Böckenholt; Funda Schürmeyer-Horst; Carsten Weishaupt; Gereon Heuft; Thomas A Luger; Gudrun Schneider
Journal:  Acta Derm Venereol       Date:  2009       Impact factor: 4.437

9.  Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin.

Authors:  R M Szeimies; W Stolz; U Wlotzke; H C Korting; M Landthaler
Journal:  Br J Dermatol       Date:  1994-09       Impact factor: 9.302

10.  Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients.

Authors:  Joanna Narbutt; Irmina Olejniczak; Dorota Sobolewska-Sztychny; Anna Sysa-Jedrzejowska; Iwona Słowik-Kwiatkowska; Tomasz Hawro; Aleksandra Lesiak
Journal:  Arch Dermatol Res       Date:  2012-10-30       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.